EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring the Role of Cardiac Troponin-Specific Autoantibodies: Prolonged Cardiac Troponin Elimination, Reduced Clearance, and Variable Interference across 5 Commercial Assays

Selma M Salonen, Jonas H Kristensen, Sara Simonen, Rasmus B Hasselbalch iD, Nina Strandkjær iD, Morten Østergaard, Hasse Møller-Sørensen iD, Morten Dahl, Mustafa Vakur Bor, Ruth Frikke-Schmidt iD, Niklas R Jørgensen, Line Rode und 8 weitere

Clinical Chemistry · 03.09.2025 · 71 (9) · 970-979

DOI: 10.1093/clinchem/hvaf077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Chemistry, online erschienen am 15.07.2025. Verfasst von Selma M Salonen und 19 weiteren Autor:innen. Beteiligte Einrichtung: Biotechnology Unit, Department of Life Technologies, University of Turku, Turku, Finland. Hauptthemen laut MEDLINE: Autoantibodies, Troponin I, Myocardial Infarction, Troponin T. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High-sensitivity cardiac troponin (hs-cTn) assays are prone to negative and positive interferences caused by endogenous cardiac troponin-specific autoantibodies (cTnAAbs). Large macrotroponin complexes formed of cardiac troponin (cTn) and cTnAAbs may result in falsely elevated hs-cTn results. This is potentially due to reduced clearance of macrotroponin, but direct evidence is still lacking. In this study, we investigated the possible effects of cTnAAbs on the elimination of cTn.

Methods

Twenty patients with ST-elevation myocardial infarction (MI) underwent plasmapheresis within 24 h after revascularization to harvest plasma with a high cTn concentration. After clinical recovery, patients returned to the hospital for autologous plasma re-transfusion. Following re-transfusion, blood samples were collected at fixed time points and analyzed with 5 commercial hs-cTn assays. The presence of cTnAAbs in the samples and the epitope specificity of cTnAAbs were investigated with in-house immunoassays.

Results

Altogether, 2 out of 20 patients (10%) were cTnAAb-positive. With 4 commercial hs-cTn assays, cTnAAb-positive patients mainly showed longer elimination half-lives and slower cTn clearances than most cTnAAb-negative patients. One hs-cTn assay was prone to negative cTnAAb interference but correspondingly less prone to positive macrotroponin interference. The central part of cardiac troponin I (cTnI) was predominantly affected by cTnAAbs.

Conclusions

Endogenous cTnAAbs were for the first time shown to prolong the elimination half-life and reduce the clearance of cTn in the circulation. Additionally, the extent of analytical interference from cTnAAbs and their reactivity to macrotroponin varies among commercial hs-cTn assays, an important consideration for laboratories to ensure accurate diagnosis of MI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantibodiesTroponin IMyocardial InfarctionTroponin THumansMaleFemaleMiddle AgedAgedImmunoassay

Substanzen

AutoantibodiesTroponin ITroponin T

Autor:innen und Institutionen

  • Biotechnology Unit, Department of Life Technologies, University of Turku, Turku, Finland.
  • Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
  • Department of Pediatrics and Adolescent Medicine, Section of Pediatric Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
  • Department of Cardiothoracic Anaesthesiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.

ORCID-Profile: Rasmus B Hasselbalch, Nina Strandkjær, Hasse Møller-Sørensen, Ruth Frikke-Schmidt, Lene Holmvang, Jesper Kjærgaard, Henning Bundgaard, Kasper K Iversen, Saara Wittfooth

Zitieren

APA

Salonen, S. M., Kristensen, J. H., Simonen, S., Hasselbalch, R. B., Strandkjær, N., Østergaard, M., Møller-Sørensen, H., Dahl, M., Bor, M. V., Frikke-Schmidt, R., Jørgensen, N. R., Rode, L., Holmvang, L., Kjærgaard, J., Bang, L. E., Forman, J., Dalhoff, K. P., Bundgaard, H., Iversen, K. K., & Wittfooth, S. (2025). Exploring the Role of Cardiac Troponin-Specific Autoantibodies: Prolonged Cardiac Troponin Elimination, Reduced Clearance, and Variable Interference across 5 Commercial Assays. Clinical Chemistry, 71(9), 970-979. https://doi.org/10.1093/clinchem/hvaf077

Vancouver

Salonen SM, Kristensen JH, Simonen S, Hasselbalch RB, Strandkjær N, Østergaard M, et al. Exploring the Role of Cardiac Troponin-Specific Autoantibodies: Prolonged Cardiac Troponin Elimination, Reduced Clearance, and Variable Interference across 5 Commercial Assays. Clinical Chemistry. 2025;71(9):970-979. doi:10.1093/clinchem/hvaf077

BibTeX
@article{Salonen2025,
  author = {Salonen, Selma M and Kristensen, Jonas H and Simonen, Sara and Hasselbalch, Rasmus B and Strandkjær, Nina and Østergaard, Morten and Møller-Sørensen, Hasse and Dahl, Morten and Bor, Mustafa Vakur and Frikke-Schmidt, Ruth and Jørgensen, Niklas R and Rode, Line and Holmvang, Lene and Kjærgaard, Jesper and Bang, Lia E and Forman, Julie and Dalhoff, Kim P and Bundgaard, Henning and Iversen, Kasper K and Wittfooth, Saara},
  title = {Exploring the Role of Cardiac Troponin-Specific Autoantibodies: Prolonged Cardiac Troponin Elimination, Reduced Clearance, and Variable Interference across 5 Commercial Assays},
  journal = {Clinical Chemistry},
  year = {2025},
  volume = {71},
  number = {9},
  pages = {970--979},
  doi = {10.1093/clinchem/hvaf077}
}
Kostenlos starten →